Clinical Neurosciences Center
U of U Professors Listed Among Utah's Health Care Heroes
Research Team Recognized for Innovative Exploration of Early Multiple Sclerosis Detection
Oct. 22, 2012
SALT LAKE CITY- Two University of Utah researchers were recently honored as Health Care Heroes by Utah Business Magazine for their innovative efforts in researching the detection of multiple sclerosis (MS) in pediatric patients.
John W. Rose, M.D., Professor of Neurology and T. Charles Casper, Ph.D., Assistant Professor of Pediatrics, University of Utah, were honored at the magazine’s annual award ceremony, which recognizes the quiet accomplishments of those working to improve the lives of others through healing and hope. Also recognized at this year’s event was an unprecedented number of University of Utah Health Care providers and volunteers.
A diagnosis of MS typically occurs in one’s midlife, yet more and more children are being diagnosed with this disabling disease each day. While an official MS diagnosis is difficult (especially in children), early detection is vital. Casper and Rose have dedicated their work to improving the diagnosis process, making life easier for both patient and caregiver.
“Once considered rare in childhood, multiple sclerosis has been increasingly identified as an important neurologic disease affecting children and adolescents, which makes early detection of the disease a key priority,” said Stefan M. Pulst, M.D., Dr. med., Professor and Chair of Neurology, University of Utah. “With the research that Drs. Rose and Casper are coordinating, important qualities and characteristics about the disease are being discovered that could result in improved early detection techniques.”
The research that Casper and Rose are analyzing will provide important clues as to how genes and environment play a role in MS. They are also working to recognize potential triggers that may lead to MS vaccines in the future.
They believe pediatric MS might hold the keys to unlocking the great mystery of the origins, triggers and development of the disease—and could further the quest to end this disease once and for all.
For more information, contact:
Paul Gadd, 801-585-7778 office, email@example.com